# A Study of IMC-A12 in Advanced Solid Tumors

> **NCT01007032** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 21 (actual)

## Conditions studied

- Tumors

## Interventions

- **BIOLOGICAL:** Cixutumumab

## Key facts

- **NCT ID:** NCT01007032
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-12
- **Final completion:** 2015-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007032, "A Study of IMC-A12 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01007032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*